WO2011149206A3 - Pharmaceutical composition containing crystalline nebivolol hydrochloride and method for preparing the same - Google Patents

Pharmaceutical composition containing crystalline nebivolol hydrochloride and method for preparing the same Download PDF

Info

Publication number
WO2011149206A3
WO2011149206A3 PCT/KR2011/003514 KR2011003514W WO2011149206A3 WO 2011149206 A3 WO2011149206 A3 WO 2011149206A3 KR 2011003514 W KR2011003514 W KR 2011003514W WO 2011149206 A3 WO2011149206 A3 WO 2011149206A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
nebivolol hydrochloride
composition containing
preparing
same
Prior art date
Application number
PCT/KR2011/003514
Other languages
French (fr)
Other versions
WO2011149206A2 (en
Inventor
Ji-Man Chae
Sung-Hoon Kam
Jae-Keol Rhee
Original Assignee
Hyundai Pharm Co., Ltd.
Bio Pharmartis Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyundai Pharm Co., Ltd., Bio Pharmartis Co., Ltd. filed Critical Hyundai Pharm Co., Ltd.
Publication of WO2011149206A2 publication Critical patent/WO2011149206A2/en
Publication of WO2011149206A3 publication Critical patent/WO2011149206A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed is a pharmaceutical composition containing crystalline nebivolol hydrochloride and a method for preparing the same that enhances the dissolution rate of the crystalline nebivolol hydrochloride and minimizes the variance of dissolution rate to greatly enhance a desired therapeutic effect. The pharmaceutical composition includes: an active ingredient including an effective amount of crystalline nebivolol hydrochloride; and a pharmaceutically acceptable additive including starch, the pharmaceutical composition containing the crystalline nebivolol hydrochloride and the starch at a weight ratio of 1:15 to 1:40.
PCT/KR2011/003514 2010-05-28 2011-05-12 Pharmaceutical composition containing crystalline nebivolol hydrochloride and method for preparing the same WO2011149206A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0050411 2010-05-28
KR1020100050411A KR20110130872A (en) 2010-05-28 2010-05-28 Pharmaceutical composition comprising crystalline nebivolol hydrochloride and method for manufacturing the same

Publications (2)

Publication Number Publication Date
WO2011149206A2 WO2011149206A2 (en) 2011-12-01
WO2011149206A3 true WO2011149206A3 (en) 2012-04-19

Family

ID=45004516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/003514 WO2011149206A2 (en) 2010-05-28 2011-05-12 Pharmaceutical composition containing crystalline nebivolol hydrochloride and method for preparing the same

Country Status (2)

Country Link
KR (1) KR20110130872A (en)
WO (1) WO2011149206A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102203229B1 (en) * 2016-01-08 2021-01-14 에리슨제약(주) Pharmaceutical composition with improved dissolution rate comprising nebivolol
WO2017119629A1 (en) * 2016-01-08 2017-07-13 에리슨제약(주) Pharmaceutical composition comprising nebivolol with improved dissolution rate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022325A1 (en) * 1994-02-17 1995-08-24 Janssen Pharmaceutica N.V. Compositions containing micronized nebivolol
EP1741712A2 (en) * 2004-07-30 2007-01-10 Torrent Pharmaceuticals Ltd Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol
KR20070044833A (en) * 2004-06-04 2007-04-30 밀란 래보러토리즈, 인크. Compositions comprising nebivolol
EP1839658A1 (en) * 2006-03-30 2007-10-03 Hexal A/S Pharmaceutical composition comprising micronized nebivolol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022325A1 (en) * 1994-02-17 1995-08-24 Janssen Pharmaceutica N.V. Compositions containing micronized nebivolol
KR20070044833A (en) * 2004-06-04 2007-04-30 밀란 래보러토리즈, 인크. Compositions comprising nebivolol
EP1741712A2 (en) * 2004-07-30 2007-01-10 Torrent Pharmaceuticals Ltd Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol
EP1839658A1 (en) * 2006-03-30 2007-10-03 Hexal A/S Pharmaceutical composition comprising micronized nebivolol

Also Published As

Publication number Publication date
WO2011149206A2 (en) 2011-12-01
KR20110130872A (en) 2011-12-06

Similar Documents

Publication Publication Date Title
WO2012035559A3 (en) Sustained release pharmaceutical compositions comprising pregabalin
MX2007007458A (en) Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof.
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
WO2010150995A3 (en) Compositions for treating drug addiction and improving addiction-related behavior
WO2010122980A8 (en) NOVEL THYROID HORMONE β RECEPTOR AGONIST
UA105766C2 (en) Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
EP2102225A4 (en) Alpha-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredient
WO2012087047A3 (en) Percutaneous absorption preparation containing rivastigmine
WO2010087565A3 (en) Novel use of piperine
WO2010097243A3 (en) Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts
WO2009140341A3 (en) Atorvastatin compositions
UA96622C2 (en) Solid dosage forms comprising aliskiren obtained by solvent-free granulation process
EP2796450A4 (en) 6-aminopyridine-3-ol derivatives or pharmaceutically acceptable salts thereof, and pharmaceutical composition containing same as active ingredients for preventing or treating diseases caused by angiogenesis
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2010090494A3 (en) Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof
MX2010007281A (en) Pharmaceutical compositions of amlodipine and valsartan.
MD4563B1 (en) Co-micronisation product comprising ulipristal acetate
SA112330457B1 (en) Phenyl-isoxazol derivatives and preparation process thereof
WO2007145863A3 (en) Sustained release formulation of naltrexone
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
EP2316420A8 (en) Method to reduce pain
WO2011132901A3 (en) Novel benzamide derivatives
WO2014006636A3 (en) Stable compositions of fesoterodine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11786839

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11786839

Country of ref document: EP

Kind code of ref document: A2